Gertjan Wolbink
Reade Rheumatology Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gertjan Wolbink as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:56 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT04251741 · Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab TreatmentReade Rheumatology Research Institute · unknown · Rheumatoid Arthritis · principal investigator
- Ph4NCT04222920 · Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease ActivityReade Rheumatology Research Institute · completed · Rheumatoid Arthritis · principal investigator
- Ph4NCT04194827 · Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug MonitoringReade Rheumatology Research Institute · unknown · Rheumatoid Arthritis · principal investigator
- Ph4NCT03895879 · Use of Tocilizumab Drug Levels to Optimize Treatment in RAReade Rheumatology Research Institute · unknown · Rheumatoid Arthritis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:56 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.Arthritis Rheum · 2005376 citationsRCR 10.3
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.Ann Rheum Dis · 2011155 citationsRCR 4.6
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.Ann Rheum Dis · 2012122 citationsRCR 4.4
- Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.Arthritis Rheum · 200995 citationsRCR 2.9
- Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis.Arch Surg · 199583 citationsRCR 2.3
- 80 citationsRCR 2.3
- Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.Ann Rheum Dis · 201858 citationsRCR 2.9
- Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.Sci Transl Med · 201955 citationsRCR 2.3
- 52 citationsRCR 1.5
- The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.Br J Cancer · 199248 citationsRCR 1.4